[1]
|
Brummendorf, T.H., Cortes, J.E., de Souza, C.A., et al. (2015) Bosutinib versus Imatinib in Newly Diagnosed Chron-ic-Phase Chronic Myeloid Leukaemia: Results from the 24-Month Follow-Up of the BELA Trial. British Journal of Haematology, 168, 69-81. https://doi.org/10.1111/bjh.13108
|
[2]
|
Cortes, J.E., Gambacorti-Passerini, C., Kim, D., et al. (2017) Effects of Bosutinib Treatment on Renal Function in Patients with Philadelphia Chromosome-Positive Leu-kemias. Clinical Lymphoma, Myeloma and Leukemia, 17, 684-695.e6.
https://doi.org/10.1016/j.clml.2017.06.001
|
[3]
|
Uzunova, K.H., Filipova, E.P. and Vekov, T.Y. (2018) Bosutinib: Valuable Therapeutic Option for the Bulgarian Market. Journal of Cancer Research and Therapeutics, 14, 909-915. https://doi.org/10.4103/jcrt.JCRT_604_16
|
[4]
|
Isfort, S. and Brummendorf, T.H. (2018) Bosutinib in Chronic Myeloid Leukemia: Patient Selection and Perspectives. Journal of Blood Medicine, 9, 43-50. https://doi.org/10.2147/JBM.S129821
|
[5]
|
Abbas, R., Leister, C. and Sonnichsen, D. (2013) A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects. Clinical Drug Investigation, 33, 589-595. https://doi.org/10.1007/s40261-013-0103-z
|
[6]
|
Gambacorti-Passerini, C., Brummendorf, T.H., Kim, D.W., et al. (2014) Bosutinib Efficacy and Safety in Chronic Phase Chronic Myeloid Leukemia after Imatinib Resistance or Intoler-ance: Minimum 24-Month Follow-Up. American Journal of Hematology, 89, 732-742. https://doi.org/10.1002/ajh.23728
|
[7]
|
Gover-Proaktor, A., Granot, G., Pasmanik-Chor, M., et al. (2019) Bosutinib, Dasatinib, Imatinib, Nilotinib, and Ponatinib Differentially Affect the Vascular Molecular Pathways and Functionality of Human Endothelial Cells. Leukemia & Lymphoma, 60, 189-199. https://doi.org/10.1080/10428194.2018.1466294
|
[8]
|
Khoury, H.J., Cortes, J., Kantarjian, H.M., et al. (2012) Bo-sutinib Is Active in Chronic Phase Chronic Myeloid Leukemia after Imatinib and Dasatinib and/or Nilotinib Therapy Failure. Blood, 119, 3403-3412.
https://doi.org/10.1182/blood-2011-11-390120
|
[9]
|
Cortes, J.E., Kantarjian, H., Shah, N.P., et al. (2012) Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias. The New England Journal of Medicine, 367, 2075-2088. https://doi.org/10.1056/NEJMoa1205127
|
[10]
|
Puttini, M., Coluccia, A.M., Boschelli, F., et al. (2006) In Vitro and in Vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 66, 11314-11322.
https://doi.org/10.1158/0008-5472.CAN-06-1199
|
[11]
|
Remsing Rix, L.L., Rix, U., Colinge, J., et al. (2009) Global Target Profile of the Kinase Inhibitor Bosutinib in Primary Chronic Myeloid Leukemia Cells. Leukemia, 23, 477-485. https://doi.org/10.1038/leu.2008.334
|
[12]
|
Cortes, J.E., Kantarjian, H.M., Brummendorf, T.H., et al. (2011) Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Imatinib. Blood, 118, 4567-4576. https://doi.org/10.1182/blood-2011-05-355594
|
[13]
|
Cortes, J.E., Gambacorti-Passerini, C., Deininger, M.W., et al. (2018) Bosutinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results from the Randomized BFORE Trial. Journal of Clinical Oncology, 36, 231-237.
https://doi.org/10.1200/JCO.2017.74.7162
|
[14]
|
Athale, U., Hijiya, N., Patterson, B.C., et al. (2019) Management of Chronic Myeloid Leukemia in Children and Adolescents: Recommendations from the Children’s Oncology Group CML Working Group. Pediatric Blood & Cancer, 66, e27827. https://doi.org/10.1002/pbc.27827
|
[15]
|
Inoue, A., Imamura, C.K., Shimada, H., et al. (2020) Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient with Chronic Myeloid Leukemia. The Journal of Pediatric Pharmacology and Therapeutics, 25, 742-745.
https://doi.org/10.5863/1551-6776-25.8.742
|
[16]
|
Cortes, J.E., Gambacorti-Passerini, C., Deininger, M., et al. (2020) Pregnancy Outcomes in Patients Treated with Bosutinib. International Journal of Hematologic Oncology, 9, IJH26. https://doi.org/10.2217/ijh-2020-0004
|
[17]
|
Chelysheva, E. and Turkina, A. (2019) Risks and Challenges of CML Management during Pregnancy: Looking for a Balanced Decision. European Journal of Haematology, 102, 378-379. https://doi.org/10.1111/ejh.13215
|
[18]
|
Abruzzese, E., de Fabritiis, P., Trawinska, M.M., et al. (2019) Back to the Future: Treatment-Free Remission and Pregnancy in Chronic Myeloid Leukemia. European Journal of Hae-matology, 102, 197-199.
https://doi.org/10.1111/ejh.13192
|
[19]
|
Cortes, J.E., Abruzzese, E., Chelysheva, E., et al. (2015) The Impact of Da-satinib on Pregnancy Outcomes. American Journal of Hematology, 90, 1111-1115. https://doi.org/10.1002/ajh.24186
|
[20]
|
Chelysheva, E., Turkina, A., Polushkina, E., et al. (2018) Placental Transfer of Tyrosine Kinase Inhibitors Used for Chronic Myeloid Leukemia Treatment. Leukemia & Lymphoma, 59, 733-738.
https://doi.org/10.1080/10428194.2017.1347929
|